NHL
Pipeline by Development Stage
Drug Modality Breakdown
Competitive Landscape
6 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (9)
Total enrollment: 417 patients across 9 trials
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Safety Study of NHL With 90Y-hLL2 IgG
Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma.
Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.